Oral administration of lactococcus lactis expressing synthetic genes of myelin antigens in decreasing experimental autoimmune encephalomyelitis in rats

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1587-1597

  Kasarello, Kaja ^a,b   Kwiatkowska Patzer, Barbara ^b   Lipkowski, Andrzej W ^b   Bardowski, Jacek K ^c   Szczepankowska, Agnieszka K ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

Autoimmune; Encephalomyelitis; Lactococcus lactis; Myelin proteins

Indexed keywords

LACTOCOCCUS LACTIS PROBIOTIC AGENT; PROBIOTIC AGENT; SYNTHETIC DNA; UNCLASSIFIED DRUG; VECTOR PLASMID; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEOLIPID PROTEIN (139-151); OLIGONUCLEOTIDE; PEPTIDE FRAGMENT; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; BACTERIUM TRANSFORMATION; BODY MASS; COLONY FORMING UNIT; CONTROLLED STUDY; DNA ISOLATION; DNA TRANSCRIPTION; ENCEPHALOMYELITIS; FEMALE; GENE; GENE EXPRESSION; GENE SEQUENCE; MOLECULAR CLONING; MYELIN GENE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; DNA SEQUENCE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LACTOCOCCUS LACTIS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; RAT;

ADMINISTRATION, ORAL; ANIMALS; BASE SEQUENCE; CLONING, MOLECULAR; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNE TOLERANCE; LACTOCOCCUS LACTIS; MOLECULAR SEQUENCE DATA; MYELIN BASIC PROTEIN; MYELIN PROTEOLIPID PROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; OLIGONUCLEOTIDES; PEPTIDE FRAGMENTS; RATS; SEQUENCE ANALYSIS, DNA;

EID: 84930664245     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892764     Document Type: Article

References (65)

1. Johnson D, Hafler DA, Fallis RJ et al: Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein and myelin basic protein in multiple sclerosis. J Neuroimmunol, 1986; 13: 99–108
2. Link H, Sun JB, Wang Z et al: Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. Neuroimmunol, 1992; 38: 63–73
3. Kerlero de Rosbo N, Milo R, Lees MB et al: Reactivity to myelin antigens in multiple sclerosis. J Clin Invest, 1993; 92: 2602–8
4. Tuohy VK: Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review. Neurochem Res, 1994; 19: 935–44
5. Tuohy VK, Fritz RB, Ben-Nun A: Self-determinants in autoimmune demyelinating disease: changes in T- cell response specificity. Curr Opin Immunol, 1994; 6: 887–91
6. Ewing C, Bernard CC: Insights into the etiology and pathogenesis of multiple sclerosis. Immunol Cell Biol, 1998; 76: 47–54
7. Hauser SL: An update on multiple sclerosis. J Neurol Sci, 2005; 228: 193–94
8. Steinman L: Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol, 2001; 13: 597–600
9. Cendrowski W: Selected issues of immunomodulating treatment in multiple sclerosis. Neurol Neurochir Pol, 2004; 38: 299–306
10. Mowat AM: The regulation of immune responses to dietary antigens. Immunol Today, 1987; 8: 93–98
11. Weiner HL, Friedman A, Miller A et al: Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol, 1994; 12: 809–37
12. Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol, 1990; 8: 579–621
13. Lees MB, Kuchroo VK, Sobel RA: Myelin proteolipid protein: its role in experimental allergic encephalomyelitis (EAE). Int Pediatr, 1991; 6: 84–90
14. Mendel I, Kerlero de Rosbo N, Ben-Nun A: A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor VB expression of encephalitogenic T cells. Eur J Immunol, 1995; 25: 1951–59
15. Higgins PJ, Weiner HL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol, 1988; 140: 440–45
16. Kelly KA, Whitacre CC: Oral tolerance in EAE: reversal of tolerance by T helper cell cytokines. J Neuroimmunol, 1996; 66: 77–84
17. Abbott DJ, Blanchfield JL, Martinson DA et al: Neuroantigen-specific, tolerogenic vaccines: GMCSFis a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE). BMC Immunology, 2011; 12: 72
18. Kwiatkowska-Patzer B, Baranowska B, Barcikowska-Litwin M, Lipkowski AW: Suppression of experimental autoimmune encephalomyelitis in the rat by oral administration of spinal cord protein hydrolysate. In: Neurochemistry. Teelken and Korf (eds.), New York: Plenum Press, 1997; 137–40
19. Kwiatkowska-Patzer B, Gajkowska B, Baranowska B, Lipkowski AW: Ultrastructural changes in the central and peripheral nervous system in the rat with experimental allergic encephalomyelitis. Folia Neuropathol, 1998; 37: 245–49
20. Kwiatkowska-Patzer B, Baranowska B, Walski M, Lipkowski AW: Influence of spinal cord protein hydrolysate upon the blood brain barrier changes due to experimental encephalomyelitis in Lewis rats. Ultrastructural study. Folia Neuropathol, 2003; 41: 29–34
21. Kwiatkowska-Patzer B, Michałkiewicz J, Kubiszewska I et al: Spinal cord hydrolysate ameliorate immunological reaction in experimental allergic encephalomyelitis. Acta Neurobiol Exp (Wars), 2009; 69: 73–78
22. Karpus WJ, Kennedy KJ, Smith WS, Miller SD: Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide. J Neurosci Res, 1996; 45: 410–23
23. Juryńczyk M, Walczak A, Jurewicz A et al: Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol, 2010; 68: 593–601
24. Levine MM: Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr, 2000; 31: 336–55
25. Modlin JF: Poliomyelitis in the United States: the final chapter? JAMA, 2004; 292: 1749–51
26. Libudzisz Z, Walczak P, Bardowski J (eds.), Lactic acid bacteria – classification, metabolism, genetics, applications (in polish). Łodź: Technical University of Łodź, 1998
27. Teusink B, Smid EJ: Modelling strategies for the industrial exploitation of lactic acid bacteria. Nat Rev Microbiol, 2006; 4: 46–56
28. Steidler L, Rottiers P: Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann NY Acad Sci, 2006; 1072: 176–86
29. Bermudez-Humaran LG, Kharrat P, Chatel J-M, Langella P: Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microbial Cell Factories, 2011; 10: S4
30. Steidler L, Hans W, Schotte L et al: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 2000; 289: 1352–55
31. Ribeiro LA, Azevedo V, Le Loir Y et al.: Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol, 2002; 68: 910–16
32. Chatel JM, Nouaille S, Adel-Patient K et al: Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice. Appl Environ Microbiol, 2003; 69: 6620–27
33. Bermudez-Humaran LG, Langella P: Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Rev Vaccines, 2010; 9: 35–44
34. Adel-Patient K, Ah-Leung S, Creminon C et al: Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy, 2005; 35: 539–46
35. Frossard CP, Steidler L, Eigenmann PA: Oral administration of an IL-10- secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J. Allergy Clin Immunol, 2007; 119: 952–59
36. Huibregtse IL, Snoeck V, de Creus A et al: Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology, 2007; 133: 517–28
37. Aleksandrzak-Piekarczyk T, Polak J, Jezierska B et al: Genetic characterization of the CcpA-dependent, cellobiose-specific PTS system comprising CelB, PtcB and PtcA that transports lactose in Lactococcus lactis IL1403. Int J Food Microbiol, 2011; 145: 186–94
38. Terzaghi BE, Sandine WE: Improved medium for lactic streptococci and their bacteriophages. Appl Microbiol, 1975; 29: 807–13
39. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a Laboratory Manual. 2nd ed. New York: Cold Spring Harbor. Cold Spring Harbor Laboratory Press, 1989
40. Holo H, Nes IF: High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris with glycine in osmotically stabilized media. Appl Environ Microbiol, 1989; 55: 3119–23
41. Wells JM, Wilson PW, Norton PM et al: Lactococcus lactis: high level expression of tetanus fragment C and protection against lethal challenge. Mol Microbiol, 1993; 8: 1155–62
42. Altschul SF, Gish W, Miller W et al: Basic local alignment search tool. J Mol Biol, 1990; 215: 403–10
43. Sun JB, Holmgren J, Czerkinsky C: Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA, 1994; 91: 10795–99
44. Ma S, Jevnikar AM: Autoantigens produced in plants for oral tolerance therapy of autoimmune diseases. Adv Exp Med Biol, 1999; 464: 179–94
45. Matsunaga Y, Wakatsuki Y, Tabata Y et al: Oral immunization with size-purified microsphere beads as a vehicle selectively induces systemic tolerance and sensitization. Vaccine, 2000; 19: 579–88
46. Gould DJ, Chernajovsky Y: Novel delivery methods to achieve immunomodulation. Curr Opin Pharmacol, 2007; 7: 445–50
47. Maassen CBM, Laman JD, van Holten-Neelen C et al: Reduced experimental autoimmune encephalomyelitis after intranasal and oral administration of recombinant lactobacilli expressing myelin antigens. Vaccine, 2003; 21: 4685–93
48. Takiishi T, Korf H, Van Belle TL et al: Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest, 2012; 122: 1717–25
49. Cortes-Perez NG, Bermudez-Humaran LG, Le Loir Y et al: Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett, 2003; 229: 37–42
50. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y et al: An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol, 2004; 53: 427–33
51. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F et al: A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol, 2005; 175: 7297–302
52. Wu C, Yang G, Bermudez-Humaran LG et al: Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)- induced asthma model mice. Int Immunopharmacol, 2006; 6: 610–15
53. Cortes-Perez NG, Ah-Leung S, Bermudez-Humaran LG et al: Intranasal coadministration of live lactococci producing interleukin-12 and a major cow’s milk allergen inhibits allergic reaction in mice. Clin Vaccine Immunol, 2007; 14: 226–33
54. Cortes-Perez NG, Ah-Leung S, Bermudez-Humaran LG et al: Allergy therapy by intranasal administration with recombinant Lactococcus lactis producing bovine beta-lactoglobulin. Int Arch Allergy Immunol, 2009; 150: 25–31
55. van Roosmalen ML, Kanninga R, El Khattabi M et al: Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from foodgrade bacteria. Methods, 2006; 38: 144–49
56. Maillard MH, Snapper SB: Teaching tolerance with a probiotic antigen delivery system. Gastroenterology, 2007; 133: 706–9
57. Amiguet P, Gardinier MV, Zanetta J-P, Matthieu J-M: Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein. J Neurochem, 1992; 58: 1676–82
58. Kowalczyk M, Cocaign-Bousquet M, Loubiere P, Bardowski J: Identification and functional characterization of cellobiose and lactose transport systems in Lactococcus lactis IL1403. Archives of Microbiology, 2008; 189: 187–96
59. Friedman A, Weiner HL: Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA, 1994; 91: 6688–92
60. Faria MCA, Maron R, Ficker SM et al: Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-b/interleukin- 10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun, 2003; 20: 135–45
61. Peng HJ, Turner MW, Strobel S: The kinetics of oral hyposensitization to a protein antigen are determined by immune status and the timing, dose and frequency of antigen administration. Immunology, 1989; 67: 425–30
62. Yoshino S: Antigen-induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after immunization. Cell Immunol, 1995; 163: 55–58
63. Meyer AL, Benson JM, Gienapp IE et al: Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol, 1996; 157: 4230–38
64. Inada S, Kohashi O, Hamasaki Y: Humoral immune-mediated acute, antigen- induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after, immunization. Immunol Invest, 2001; 30: 47–56
65. Lamont AG, Bruce MG, Watret KC, Ferguson A: Suppression of an established DTH response to ovalbumin in mice by feeding antigen after immunization. Immunology, 1988; 64: 135–39